Low Dose Naltrexone (LDN) and Melanoma: A Case Study

This presentation explores the potential of Low-Dose Naltrexone (LDN) in cancer treatment, focusing on a compelling index case. A 70-year-old man with head and neck melanoma, previously stabilized with a Mycobacterium Vaccae vaccine, experienced metastatic progression. After refusing chemotherapy, he opted for LDN, which rapidly induced vitiligo, signaling activated immune response. This case highlights LDN's promising role in enhancing anti-tumor immunity.

Professor Angus Dalgleish:  In this case, 70-year-old man with head and neck melanoma stabilized for years on non-specific immunotherapy, another agent which I had identified as inducing clear benefit in patients with melanoma and as it subsequently found out many other conditions was microacterium vaci which is a heatkilled intrammal injection. We originally called it a vaccine but it really is an intrammal immune modulator and appeared to enhance the effect of surgery radiotherapy and chemotherapy for stop. This patient was a doctor and the increase of his metastasis and his neck and lung meant that he really should consider chemotherapy. But being a doctor, he was aware of the very low chance of the chemotherapy available at that time having any significant benefit other than guaranteed toxicity. He accepted my offer to give him lowd dose nrexone. And what was really quite incredible was that when I followed him up in two weeks time, he complained that it had induced vitiligo across his body within 48 hours. We'll stop. He felt that this was a terrible thing as it meant he wouldn't be able to go sunbathing which was really the cause of his melanoma in the first place. What vitiligo means in melanoma patients is that they have activated specific cytotoxic tlymphosytes against tyroinesise and in every case where this had happened in previous imunotherapy uh programs with interferon or interlucan 2 or in the many vaccine programs I had been involved with this indication of itigo is associ assiated with a fantastic prognostic outcome. And indeed, this patient lived another 10 years.